The Global Burden of Pulmonary Embolism Management: Epidemiology and Statistics
Disclaimer
This article is intended for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Introduction
Pulmonary embolism (PE), a severe manifestation of venous thromboembolism (VTE), represents a significant global health challenge. It occurs when a blood clot, often originating from deep veins in the legs (deep vein thrombosis or DVT), travels to the lungs, obstructing blood flow and potentially leading to life-threatening consequences. The global burden of PE is substantial, impacting millions worldwide and contributing significantly to morbidity and mortality. This comprehensive review delves into the epidemiology and statistics of PE, highlighting its incidence, prevalence, mortality trends, and the disparities observed across different regions and socioeconomic strata. Understanding these dynamics is crucial for developing effective prevention strategies, improving diagnostic accuracy, and optimizing management protocols.
Epidemiology of Pulmonary Embolism
Incidence and Prevalence
The incidence and prevalence of PE vary considerably across geographical regions and populations. Epidemiological studies have shown a wide range of incidence rates, from as low as 14 per 100,000 persons in China to 115 per 100,000 persons per year in the United States [3, 5]. These variations can be attributed to differences in genetic predispositions, lifestyle factors, healthcare access, and diagnostic practices. Despite advancements in medical science, the overall burden remains high, with an estimated 10 million cases of DVT and PE diagnosed globally each year [6].
Mortality Rates and Trends
Globally, PE-related mortality rates have shown a complex trend over the past two decades. A recent epidemiological analysis of data from the World Health Organization (WHO) Mortality Database from 2001 to 2023 revealed a general decline in the age-standardized PE-related mortality rate from 3.49 per 100,000 in 2001 to 2.42 per 100,000 in 2023 [1]. This downward trend is particularly evident in high-income countries and Western European regions, where significant reductions in mortality have been observed. For instance, Western Europe saw a decrease from 5.24 to 2.25 per 100,000 during the same period [1].
However, this positive trend is not universal. Lower-to middle-income countries have experienced a concerning rise in age-standardized mortality rates, increasing from 0.92 per 100,000 in 2001 to 4.82 per 100,000 in 2023 [1]. Africa also maintained high mortality rates throughout the study period, dropping only slightly from 4.23 to 3.90 per 100,000 [1]. These disparities underscore the critical influence of healthcare infrastructure, access to diagnostic tools, and effective treatment on patient outcomes.
Regional and Economic Disparities
The observed regional and economic disparities in PE mortality are profound. High-income countries, benefiting from advanced diagnostic capabilities, improved therapeutic options, and established clinical guidelines, have largely succeeded in reducing PE-related deaths. In contrast, lower-middle-income countries often face significant challenges, including limited access to healthcare services, lack of advanced diagnostic imaging (such as computed tomography), and insufficient availability of effective anticoagulants [1]. These factors contribute to delayed diagnosis, suboptimal treatment, and consequently, higher mortality rates.
Furthermore, studies have indicated that certain demographic groups within countries may experience higher mortality. For example, a nationwide US analysis highlighted that women, middle-aged adults, and non-Hispanic Black individuals had higher mortality rates from concurrent PE and obesity [2]. These findings emphasize the need for targeted interventions and equitable distribution of healthcare resources to address these vulnerable populations.
Risk Factors and Contributing Elements
Pulmonary embolism is associated with a diverse range of risk factors, including surgery, malignancy, advanced age, and obesity [1]. The global increase in obesity rates is a particularly noteworthy concern, as it significantly elevates the risk of VTE. From 1999 to 2020, the age-adjusted mortality rate for PE with obesity in the US increased from 5.1 to 13.9 per 1,000,000, with a sharper increase observed between 2018 and 2020 [2]. This trend suggests that the rising prevalence of obesity could be counteracting some of the gains made in PE management.
Other contributing factors include prolonged immobility, genetic thrombophilias, hormonal therapy, and certain medical conditions like cancer. The growing incidence of cancer worldwide also plays a role, as cancer patients are at an increased risk of developing PE [1].
Advances in Diagnosis and Management
Significant progress has been made in the diagnosis and management of PE, contributing to the overall decline in mortality rates in many regions.
Diagnostic Tools
Modern diagnostic approaches have become increasingly sophisticated. Clinical decision rules, such as the Wells score and revised Geneva score, aid in risk stratification and guide the need for further testing [28]. The D-dimer test, a sensitive laboratory indicator, helps in ruling out PE, especially when combined with clinical probability assessment [29]. However, its specificity can be limited, particularly in older or hospitalized patients, leading to the development of age-adjusted D-dimer testing [30].
Advanced imaging techniques, including enhanced computed tomography pulmonary angiography (CTPA) and ventilation-perfusion (V/Q) lung scanning, have revolutionized the early and accurate detection of PE. While CTPA is widely used, it\'s important to note that a negative result does not entirely exclude PE in all cases [29].
Therapeutic Strategies
The therapeutic landscape for PE has also evolved considerably. The introduction of direct oral anticoagulants (DOACs) has simplified treatment regimens, offering rapid onset of action, reduced bleeding risk, and eliminating the need for routine laboratory monitoring compared to traditional anticoagulants [31, 32, 33]. These advancements have significantly improved the effectiveness and safety of PE treatment.
For high-risk patients, more aggressive interventions such as catheter-directed thrombolysis or surgical embolectomy may be considered. The development of multidisciplinary Pulmonary Embolism Response Teams (PERT) has also improved patient outcomes by facilitating rapid assessment and individualized treatment plans [11].
Challenges in Global PE Management
Despite these advancements, several challenges persist in global PE management. The most prominent is the stark disparity in healthcare access and quality between high-income and lower-middle-income countries. Limited resources, lack of trained personnel, and inadequate infrastructure hinder the implementation of effective diagnostic and treatment protocols in many parts of the world [1].
Furthermore, the increasing prevalence of risk factors like obesity and an aging global population continue to pose significant challenges. The non-specific nature of PE symptoms often leads to misdiagnosis or delayed diagnosis, particularly in settings with limited diagnostic capabilities [1]. Underreporting of PE as a cause of death in some regions also complicates accurate epidemiological assessment [1].
Conclusion
Pulmonary embolism remains a critical global health concern, characterized by complex epidemiological trends and significant disparities in management outcomes. While high-income countries have made considerable strides in reducing PE-related mortality through advanced diagnostics and therapeutics, lower-middle-income countries continue to bear a disproportionately high burden. Addressing these global disparities requires a multi-faceted approach, including strengthening healthcare systems, improving access to diagnostic and treatment modalities, and implementing targeted public health initiatives to mitigate risk factors. Continued research and international collaboration are essential to further unravel the complexities of PE and to ensure equitable access to life-saving interventions worldwide.
References
[1] Hagiya, H., Harada, K., Nishimura, Y., et al. (2025). Global trends in mortality related to pulmonary embolism: an epidemiological analysis of data from the World Health Organization mortality database from 2001 to 2023. *eClinicalMedicine*, 86, 103389. [https://doi.org/10.1016/j.eclinm.2025.103389](https://doi.org/10.1016/j.eclinm.2025.103389)
[2] Goyal, A., Saeed, H., Sulaiman, S. A., et al. (2025). Disparities and trends in pulmonary embolism mortality with and without obesity: a nationwide US analysis. *Research and Practice in Thrombosis and Haemostasis*, 9(8), 103240. [https://doi.org/10.1016/j.rpth.2025.103240](https://doi.org/10.1016/j.rpth.2025.103240)
[3] Zhen, K., Tao, Y., Xia, L., et al. (2025). Epidemiology of pulmonary embolism in China, 2021: a nationwide hospital-based study. *Lancet Reg Health West Pac*, 54, 101258. [https://doi.org/10.1016/j.lanwpc.2024.101258](https://doi.org/10.1016/j.lanwpc.2024.101258)
[5] Centers for Disease Control and Prevention (CDC). (2012). Venous thromboembolism in adult hospitalizations – United States 2007–2009. *MMWR Morb Mortal Wkly Rep*, 61, 401–404. [https://pubmed.ncbi.nlm.nih.gov/22672974](https://pubmed.ncbi.nlm.nih.gov/22672974)
[6] "Pulmonary Embolism: An International Crisis." *EV Today*, July 2019. [https://evtoday.com/articles/2019-july-supplement/pulmonary-embolism-an-international-crisis](https://evtoday.com/articles/2019-july-supplement/pulmonary-embolism-an-international-crisis)
[11] Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016). Management of pulmonary embolism: an update. *J Am Coll Cardiol*, 67, 976–990. [https://doi.org/10.1016/j.jacc.2015.11.061](https://doi.org/10.1016/j.jacc.2015.11.061)
[28] Kline, J. A., Mitchell, A. M., Kabrhel, C., Richman, P. B., & Courtney, D. M. (2004). Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. *J Thromb Haemost*, 2, 1247–1255. [https://doi.org/10.1111/j.1538-7836.2004.00790.x](https://doi.org/10.1111/j.1538-7836.2004.00790.x)
[29] Kahn, S. R., & de Wit, K. (2022). Pulmonary embolism. *N Engl J Med*, 387, 45–57. [https://doi.org/10.1056/NEJMcp2116489](https://doi.org/10.1056/NEJMcp2116489)
[30] Van Es, N., Van Der Hulle, T., Van Es, J., et al. (2016). Wells rule and d-dimer testing to rule out pulmonary embolism: a systematic review and individual-patient data meta-analysis. *Ann Intern Med*, 165, 253–261. [https://doi.org/10.7326/M16-0031](https://doi.org/10.7326/M16-0031)
[31] Chai-Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., & Crowther, M. (2015). Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *J Thromb Haemost*, 13, 2012–2020. [https://doi.org/10.1111/jth.13139](https://doi.org/10.1111/jth.13139)
[32] Li, M., Li, J., Wang, X., et al. (2023). Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. *Cochrane Database Syst Rev*, 4, CD010957. [https://doi.org/10.1002/14651858.CD010957.pub3](https://doi.org/10.1002/14651858.CD010957.pub3)
[33] Eldredge, J. B., & Spyropoulos, A. C. (2018). Direct oral anticoagulants in the treatment of pulmonary embolism. *Curr Med Res Opin*, 34, 131–140. [https://doi.org/10.1080/03007995.2017.1364227](https://doi.org/10.1080/03007995.2017.1364227)